KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other financing activities: 2020-2025

Historic Other financing activities for Royalty Pharma (RPRX) over the last 1 years, with Sep 2025 value amounting to $13.5 million.

  • Royalty Pharma's Other financing activities rose 338.57% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.5 million, marking a year-over-year increase of 171.18%. This contributed to the annual value of $12.6 million for FY2024, which is 690.48% up from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Other financing activities is $13.5 million, which was up 4,414.33% from $300,000 recorded in Q4 2024.
  • In the past 5 years, Royalty Pharma's Other financing activities registered a high of $13.5 million during Q3 2025, and its lowest value of $300,000 during Q4 2024.
  • For the 3-year period, Royalty Pharma's Other financing activities averaged around $4.6 million, with its median value being $2.3 million (2023).
  • As far as peak fluctuations go, Royalty Pharma's Other financing activities soared by 430.46% in 2021, and later crashed by 81.20% in 2024.
  • Quarterly analysis of 5 years shows Royalty Pharma's Other financing activities stood at $801,000 in 2021, then surged by 68.16% to $1.3 million in 2022, then grew by 18.49% to $1.6 million in 2023, then plummeted by 81.20% to $300,000 in 2024, then spiked by 338.57% to $13.5 million in 2025.
  • Its Other financing activities stands at $13.5 million for Q3 2025, versus $300,000 for Q4 2024 and $3.1 million for Q3 2024.